| Ytd | 0.10% | |
| 1y | 98.27% |
| Open | 79.13 | Prev Close | 79.29 | Low | 77.95 | High | 79.48 | Mkt Cap | 13.09B |
| Vol | 1.43M | Avg Vol | 1.82M | EPS | -2.01 | P/E | N/A | Forward P/E | -130.13 |
| Beta | 0.37 | Short Ratio | 10.30 | Inst. Own | 107.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 75.32 | 200-d Avg | 75.65 | 1yr Est | 105.91 |
Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. comm
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridem
Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutra
The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.'s (NAS
Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing
Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outpe
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)
- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access
Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outpe
TD Cowen analyst Yaron Werber reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maint
Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)